HIV Infections Clinical Trial
— PPTOfficial title:
Evaluation of Presumptive Periodic Treatment (PPT) of Sexually Transmitted Infections (STIs) Among High-risk Populations Including Men Who Have Sex With Men, Female Sex Workers (FSW) and Mining Populations in Tanzania.
NCT number | NCT04036318 |
Other study ID # | 16.02.PPT |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 14, 2018 |
Est. completion date | August 13, 2019 |
Verified date | September 2020 |
Source | National Institute for Medical Research, Tanzania |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Sexually transmitted infections (STI) are important causes of reproductive health morbidity
and mortality, and have long been implicated as major co-factors in the sexual transmission
of HIV. Both ulcerative and non-ulcerative STI have been found to be strongly associated with
HIV in cross-sectional and prospective studies and hence STI prevention and care are
important aspects of HIV prevention.
Periodic Presumptive Treatment of STIS (PPT) where risk populations are presumptively treated
with a single dose of Azithromycin+Cefixime in regular intervals of 3 months has been shown
to be effective in reducing STI prevalence at population level and has recently been
integrated into the National STI guidelines of Tanzania. The USAID funded Sauti program will
be one of the first to implement these new guidelines and roll out PPT in high risk
populations in selected regions in Tanzania. This study will evaluate the impact of PPT as
delivered by the Sauti program on prevalence of STIs in men who have sex with men and female
sex workers in Dar es Salaam and Shinyanga respectively.
Status | Completed |
Enrollment | 3022 |
Est. completion date | August 13, 2019 |
Est. primary completion date | August 13, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Willing to give oral informed consent - 18 years of age or older - Is referred from the pre-selected recruitment venues and present and recruitment card. - Sexually active in the last 6 months - At least half of self-reported monthly income is generated through sex work (FSWs only) - Men who engage in sexual relations with other men regardless of the motivation (MSMs only) Exclusion Criteria: - Not willing to give informed consent - Not sexually active in the last 6 months - State of intoxication from recreational drugs or alcohol use or other reasons which would prevent voluntary and informed consent to the study as judged by investigator - Pregnant women - (determined through pregnancy screening questions used by Sauti) - Does not have a study referral card |
Country | Name | City | State |
---|---|---|---|
Tanzania | Dar es Salaam region | Dar es Salaam | Temeke |
Tanzania | Shinyanga Region | Shinyanga | Kahama |
Lead Sponsor | Collaborator |
---|---|
National Institute for Medical Research, Tanzania |
Tanzania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduction of prevalence of laboratory confirmed bacterial STIs | Reduction in prevalence of laboratory confirmed STIs (a combined measure of gonorrhea, chlamydia and Treponema pallidum) in men who have sex with men (MSMs) in Dar es Salaam and female sex workers (FSWs) in Shinyanga after six months of presumptive treatment of STIs (PPT). | After six months of periodic presumptive treatment of STIs | |
Primary | Reduction of prevalence of syndromic STIs | Syndromic STI prevalence (Genital ulcers disease (GUD), Anorectal Syndrome (ARS), Urethral Discharge Syndrome (UDS), Painful scrotal swelling (PSS)) among male clients of FSW in Shinyanga mines (bridge population) after six months of availability of PPT to FSWs. initiation. | After six months of periodic presumptive treatment of STIs among FSW in Shinyanga | |
Secondary | Associations between demographic, socio-economic, behavioral and biological risk factors, STI prevalence and PPT impact. | The association will determined by using the logistic regression | After six months of periodic presumptive treatment of STIs among FSW in Shinyanga | |
Secondary | Changes in sexual risk taking behaviors while receiving PPT | Changes in sexual risk behaviors will be determined by comparing the baseline prevalence and prevalence after six months of PPT | Six months | |
Secondary | Prevalence of cervical cancer lesions | The prevalence of cervical cancer lesions, will be assessed through Visual Inspection with Acetic Acid (VIA), among the FSW in the study. | Six months | |
Secondary | Prevalence of Human Papilloma Virus (HPV), HIV, Hepatitis B and C | The prevalence of Human Papilloma Virus (HPV), HIV, Hepatitis B and C will be assessed from the bio-specimens of serum and genital swabs collected during the surveys | Six months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |